Chimeric’s CEO and managing director, Jennifer Chow, said, “We are delighted with USPTO’s decision to grant patent protection for our CORE-NK platform in the United States, the single largest global market for biopharmaceutical products." …
Chimeric secures US patent for its CHM 0201 cell therapy platform technology
April 8, 2024 Australian Biotech
Latest Video
New Stories
-
Australia's 2026 flu vaccination season barely moves the needle on uptake
September 15, 2026 - - Latest News -
Persistent fatigue could be an overlooked sign of liver disease
September 15, 2026 - - Latest News -
Noxopharm moves lupus skin therapy toward next human trial
September 14, 2026 - - Australian Biotech -
Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends
September 14, 2026 - - Latest News -
Diabetes and cancer blood tests reach WA and NT patients under new Healius deal
September 14, 2026 - - Australian Biotech -
FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug
September 14, 2026 - - Australian Biotech -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News